←Back to list

Transcarent

Developer of consumer-directed health and care platform intended to facilitate improved outcomes and cost-effective deci
Developer of consumer-directed health and care platform intended to facilitate improved outcomes and cost-effective decisions.
Clinics/Outpatient Services 📍 Denver, CO Founded 2020
Current Valuation
$2.7B
as of 2025-Q2
UNICORN

QL Price

$1.9B
-29% vs last round
QuantLogix's current estimate for Transcarent, published 2026-09-07 — below the last disclosed round of $2.7B (2025-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $2.7B 2025-Q2 weight 0.44
Secondary market print $1.4B 2026-06-27 weight 0.65
How this price has held up
No round has priced for Transcarent since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-07 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Transcarent →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Transcarent, 2026-09-07 (199247440c8a9d53). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Transcarent going public?
No. Transcarent is private and has not filed to go public. There is no S-1 on file.
What is Transcarent's valuation in 2026?
Transcarent is valued at $2.7B as of 2025-Q2, set by its Series D1 ($200M, Apr 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Transcarent filed an S-1?
No public S-1 is on file for Transcarent.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2020
HQ
Denver, CO
Employees
454
Total Raised
$905M
Last Round
Series D1 — $200M (Apr 2025)
IPO Status
private

Fundraising Status

Series D1 · $200M · 1y 5mo ago
privateTotal raised $905M

Secondary Market

Implied price / share
$10.38
Last round price / share
$20.48
vs last round
-49.3%
Last round price vs secondary price
Last round vs current secondary price per share$20.48Last round$10.38Current
Secondary price return by period
Secondary market period returns3-month0.0%6-month+2.7%1-year-28.2%All-time-45.4%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series D1$200MApr 2025—$2.7B

Talent Signal

Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
4
via careers page
Product-build share
50%
engineering, research, product, design
Trajectory
steady
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month4Aug '26
Open roles by function
Open roles by functionClinical & Science2Ops & People1Support1
■ product-building   ■ go-to-market / G&A
AFFILIATED MEDICAL GROUP OPENINGSComprehensive medical, dental, and vision coveragePeople FirstPaid parental leave and caregiver support
Counted from Transcarent's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CarePersonal HealthSoftware
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.